SEC Tracker
Get the app
RCKT · XBRL financial data

Rocket Pharmaceuticals financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (RCKT's year ends in late December)

In millions of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Revenue from contracts with customers00*0000*0000*00
Research and development4742*45464237*36433429*3129
General and administrative1922*22272725*28251815*1717
Total operating expenses6563*67746963*64715244*4947
Operating income (loss)(65)(63)*(67)(74)(69)(63)*(64)(71)(52)(44)*(49)(47)
Interest expense00*0000*0000*00
Income tax expense (benefit)—year only———year only—0—year only—9
Net income (loss)(62)(60)*(62)(70)(67)(60)*(61)(69)(50)(43)*(48)123
Earnings per share, basic USD per share(0.75)(0.64)*(0.66)(0.74)(0.71)(0.62)*(0.56)(0.62)(0.45)(0.38)*(0.42)1.09
Earnings per share, diluted USD per share(0.75)(0.64)*(0.66)(0.74)(0.71)(0.62)*(0.56)(0.62)(0.45)(0.38)*(0.42)1.08
Weighted average shares, basic millions of shares8393*94949498*110111112112*112113
Weighted average shares, diluted millions of shares8393*94949498*110111112112*112115

Balance sheet

CSV

Fiscal quarters (RCKT's year ends in late December)

In millions of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents226563539661645033767850225
Short-term investments2123172952401702092682391471119559
Prepaid and other current assets105151466665456
Total current assets447378345293242378324277228193150290
Property and equipment, net373939403937353330282725
Right-of-use asset445544444333
Goodwill393939393939393939393939
Total assets599566499446394528471421368330285423
Total current liabilities334933384041354331302431
Lease liability, non-current334433333322
Total liabilities587458626464596754534754
Accumulated deficit(900)(959)(1,021)(1,091)(1,158)(1,218)(1,279)(1,348)(1,399)(1,441)(1,489)(1,366)
Total stockholders' equity541493442385330463412354314277238369
Total liabilities and equity599566499446394528471421368330285423
Common shares outstanding (cover page) millions of shares9091919191107108108108109109110

Cash flows

CSV

Fiscal quarters (RCKT's year ends in late December)

In millions of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Net income (loss)(62)(60)*(62)(70)(67)(60)*(61)(69)(50)(43)*(48)123
Stock-based compensation10*10*1011*11*11*1011*10*6*87*
Depreciation and amortization11*2222*3232*22
Net cash from operating activities(57)*(29)*(57)(54)*(52)*(47)*(56)(49)*(50)*(35)*(45)(40)*
Purchases of property and equipment5*5*22*2*0*00*(0)*0*00*
Net cash from investing activities48*(141)*3556*79*(38)*(58)32*94*36*17214*
Proceeds from issuing common stock0*—00*————————
Net cash from financing activities189*0*12*0*183*00*(0)*0*(0)0*

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($M)Revenue, quarter ($M)Operating cash flow, quarter ($M)Shares outstandingRunwayQuarter
Rocket Pharmaceuticals2250(40)*109.8M7.2 quarters 10-QJun 30, 2026
Perspective Therapeutics48not reported(21)*114.2M11.5 quarters 10-QJun 30, 2026
Natures Sunshine Products831170.8*17.6M— 10-QJun 30, 2026
Tvardi Therapeutics16not reported(9.2)*13.3M1.7 quarters 10-QJun 30, 2026
Silence Therapeutics7201.5*141.7M— 10-QJun 30, 2026
SELLAS Life Sciences Group138not reported(7.6)*201.9M18.2 quarters 10-QJun 30, 2026
Precigen1655(18)*358.0M2.1 quarters 10-QJun 30, 2026
Cardiff Oncology9.20.1(12)*77.8M2.9 quarters 10-QJun 30, 2026
Rezolute11not reported(13)*96.7M8.2 quarters 10-KJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.